News

Beactica awarded funding to develop new therapeutics against aggressive brain tumours

Beactica, the Swedish drug discovery company, today announced that it has been awarded 2 MSEK (~$240 000) by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its LSD1 programme. This programme aims to develop a novel class of compounds with the potential to radically improve the current treatment... [...]

Beactica to present at the 15th Annual Discovery On Target Conference in Boston, MA

Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for both an oral and a poster presentation at the 15th Annual Discovery on Target Conference (www.discoveryontarget.com). The conference will take place on September 25–29, 2017 at The Westin Copley Place in Boston,... [...]

Beactica participates in EU training network on fragment-based drug discovery

Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called FRAGNET, is funded with 3.9 MEUR by the EU and aims to deliver 15 skilled early-stage researchers in the field of fragment-based drug discovery (FBDD).“Training... [...]

Beactica announces appointment of Scientific Advisors

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Professor Jan Kihlberg and Dr Vendela Parrow as Scientific Advisors. They will, together with company co-founder Professor Helena Danielson, assist the progression of Beactica’s internal drug discovery programs within oncology... [...]

Beactica Appoints Dr Ulf Bremberg as Chief Scientific Officer

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Ulf Bremberg as Chief Scientific Officer. "We are delighted to have Ulf join Beactica at an important time for the company.” said Dr Per Källblad, CEO of Beactica. "As our internal pipeline is advancing, the appointment... [...]

Beactica expands into new premises

Beactica, the Swedish fragment-based drug discovery company, today announced its move into new premises at the Uppsala Business Park. "The move to the new premises give us excellent opportunities to expand as the company grows.” said Beactica’s COO, Dr Malin Elinder. "Our international collaboration partners will... [...]

Beactica scientists publish strategies for discovery of allosteric modulators

Beactica, the Swedish fragment-based drug discovery company, today announced the publication of a key paper in Proceedings of the National Academy of Sciences*. The paper describes important work towards the discovery of novel drugs targeting ligand-gated ion channels, a significant family of drug targets involved in... [...]